<?xml version="1.0" encoding="UTF-8"?>
<p>Although the landmark zidovudine trial paved the way for rigorous study of HIV antiretrovirals in pregnancy [
 <xref rid="pmed.1002882.ref021" ref-type="bibr">21</xref>], this has yet to translate to the TB arena. TB treatment in pregnancy and lactation is mostly based on case reports and small case series [
 <xref rid="pmed.1002882.ref006" ref-type="bibr">6</xref>,
 <xref rid="pmed.1002882.ref007" ref-type="bibr">7</xref>,
 <xref rid="pmed.1002882.ref022" ref-type="bibr">22</xref>]. As a result, medications, including those for TB, are often prescribed in pregnancy without the knowledge required to achieve appropriate doses for optimal therapeutic effect [
 <xref rid="pmed.1002882.ref023" ref-type="bibr">23</xref>,
 <xref rid="pmed.1002882.ref024" ref-type="bibr">24</xref>], and WHO and Centers for Disease Control and Prevention (CDC) recommend conflicting treatment guidelines for drug-susceptible TB (i.e., 6-month regimen, including pyrazinamide versus 9-month regimen, excluding pyrazinamide, respectively) [
 <xref rid="pmed.1002882.ref025" ref-type="bibr">25</xref>,
 <xref rid="pmed.1002882.ref026" ref-type="bibr">26</xref>]. Overall, uncertainty persists concerning optimal drug selection, safety, and timing of TB treatment initiation and whether safety signals differ by trimester.
</p>
